{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T02:48:47Z","timestamp":1793501327666,"version":"4.5.0"},"posted":{"date-parts":[[2025,10,16]]},"group-title":"In Review","reference-count":40,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,9,30]]},"abstract":"<title>Abstract<\/title>\n                <p>\n                  <bold>Background<\/bold>\n                  : Plasma p-tau217 is a promising biomarker for detecting incipient AD pathology, but direct comparison of different p-tau217 assays in community-based cohorts are limited.\n                  <bold>Methods<\/bold>\n                  : We evaluated two cohorts from southwestern Pennsylvania, USA; the MYHAT-NI sub-study, which included two-year longitudinal follow-up neuroimaging assessments of A\u03b2, tau, and cortical thickness; and the Human Connectome Project\/CoBRA, targeting a 50:50 split of self-identified Black and non-Hispanic White individuals. Plasma p-tau217 was measured using four different assays: Lumipulse, Johnson&amp;Johnson, ALZpath, and NULISA. A\u03b2 and tau pathologies were assessed with [\n                  <sup>11<\/sup>\n                  C]PiB PET and [\n                  <sup>18<\/sup>\n                  F]Flortaucipir PET, respectively. Clinical Dementia Rating (CDR) and Montreal Cognitive Assessment were used to assess cognitive performance.\n                  <bold>Results<\/bold>\n                  : We included 344 participants (MYHAT-NI: n=111, median age 76 [IQR: 72-80], 54% female; HCP\/CoBRA: n=234, median age 62 [IQR: 52-70], 65% female). All four p-tau217 assays exhibited moderate to strong cross-platform correlations (Spearman correlations of 0.40 \u2013 0.86), and statistically equivalent AUCs (of 0.84-0.90) for determining A\u03b2 positivity.\n                  <bold>Conclusions<\/bold>\n                  : Our findings showed strong equivalent performances of plasma p-tau217 assays to identify amyloid positivity across two highly diverse cohorts of community-dwelling older adults.\n                <\/p>","DOI":"10.21203\/rs.3.rs-7754328\/v1","type":"posted-content","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T18:28:03Z","timestamp":1760639283000},"source":"Crossref","is-referenced-by-count":1,"title":["Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer\u2019s disease in community cohorts"],"prefix":"10.21203","author":[{"given":"Rebecca A.","family":"Deek","sequence":"first","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasiu G.","family":"Balogun","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmuth C.","family":"Kolb","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Snitz","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","article-title":"Blood-based biomarkers for Alzheimer's disease: towards clinical implementation","volume":"21","author":"Teunissen CE","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21(1):66\u201377.","journal-title":"Lancet Neurol"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13195-022-01023-6","article-title":"Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217 [published correction appears in","volume":"14","author":"Groot C","year":"2022","unstructured":"Groot C, Cicognola C, Bali D, et al. Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217 [published correction appears in. Alzheimers Res Ther. 2022;14(1):82.","journal-title":"Alzheimers Res Ther"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1038\/s41591-025-03605-x","article-title":"Blood-based biomarkers of Alzheimer\u2019s disease and incident dementia in the community","volume":"31","author":"Grande G","year":"2025","unstructured":"Grande G, Valletta M, Rizzuto D, et al. Blood-based biomarkers of Alzheimer\u2019s disease and incident dementia in the community. Nat Med. 2025;31:2027\u201335.","journal-title":"Nat Med"},{"issue":"7618","key":"ref4","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease","volume":"537","author":"Sevigny J","year":"2016","unstructured":"Sevigny J, Chiao P, Bussi\u00e8re T, et al. The antibody aducanumab reduces A\u03b2 plaques in Alzheimer's disease. Nature. 2016;537(7618):50\u20136.","journal-title":"Nature"},{"issue":"18","key":"ref5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun MA","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. N Engl J Med. 2021;384(18):1691\u2013704.","journal-title":"N Engl J Med"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton NJ","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"key":"ref7","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease","volume":"28","author":"Mil\u00e0-Alom\u00e0 M","year":"2022","unstructured":"Mil\u00e0-Alom\u00e0 M, Ashton NJ, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer\u2019s disease. Nat Med. 2022;28:1797\u2013801.","journal-title":"Nat Med"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist S","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324(8):772\u201381.","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","article-title":"Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring","volume":"28","author":"Ashton NJ","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28:2555\u201362.","journal-title":"Nat Med"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"e70409","DOI":"10.1002\/alz.70409","article-title":"Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community","volume":"21","author":"Sehrawat A","year":"2025","unstructured":"Sehrawat A, Zeng X, Abrahamson EE, et al. Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community. Alzheimers Dement. 2025;21(7):e70409.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/alz.13525","article-title":"A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease","volume":"20","author":"Gonzalez-Ortiz F","year":"2024","unstructured":"Gonzalez-Ortiz F, Ferreira PCL, Gonz\u00e1lez-Escalante A, et al. A novel ultrasensitive assay for plasma p-tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease. Alzheimers Dement. 2024;20(2):1239\u201349.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari TK","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","article-title":"Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative","volume":"26","author":"Karikari TK","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry. 2021;26:429\u201342.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","article-title":"Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology","volume":"141","author":"Ashton NJ","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021;141(5):709\u201324.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"e70209","DOI":"10.1002\/alz.70209","article-title":"Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease","volume":"21","author":"Bellaver B","year":"2025","unstructured":"Bellaver B, Povala G, Ferreira PCL, et al. Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer's disease. Alzheimers Dement. 2025;21(5):e70209.","journal-title":"Alzheimers Dement"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee P","year":"2021","unstructured":"Chatterjee P, Pedrini S, Stoops E, et al. Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease. Transl Psychiatry. 2021;11:27.","journal-title":"Transl Psychiatry"},{"issue":"17","key":"ref17","doi-asserted-by":"crossref","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","article-title":"High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis","volume":"93","author":"Schindler SE","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","article-title":"Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status","volume":"15","author":"Bun S","year":"2023","unstructured":"Bun S, Ito D, Tezuka T, et al. Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status. Alz Res Therapy. 2023;15:149.","journal-title":"Alz Res Therapy"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","article-title":"Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort","volume":"271","author":"Mendes AJ","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271(4):2053\u201366.","journal-title":"J Neurol"},{"issue":"4","key":"ref20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jagp.2024.09.015","article-title":"Where Do Plasma Biomarkers fit in With Current Alzheimer's Disease Detection?","volume":"33","author":"Gildengers A","year":"2025","unstructured":"Gildengers A, Weinstein AM, Gujral S, et al. Where Do Plasma Biomarkers fit in With Current Alzheimer's Disease Detection? Am J Geriatr Psychiatry. 2025;33(4):428\u201337.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"e12514","DOI":"10.1002\/dad2.12514","article-title":"Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study","volume":"15","author":"Xiao Z","year":"2023","unstructured":"Xiao Z, Wu W, Ma X, et al. Plasma p-tau217, p-tau181, and NfL as early indicators of dementia risk in a community cohort: The Shanghai Aging Study. Alzheimers Dement (Amst). 2023;15(4):e12514.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","article-title":"Plasma phosphorylated tau 217 in preclinical Alzheimer's disease","volume":"5","author":"Jonaitis EM","year":"2023","unstructured":"Jonaitis EM, Janelidze S, Cody KA, et al. Plasma phosphorylated tau 217 in preclinical Alzheimer's disease. Brain Commun. 2023;5(2):fcad057.","journal-title":"Brain Commun"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13195-025-01803-w","article-title":"Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort","volume":"17","author":"Dresse MT","year":"2025","unstructured":"Dresse MT, Ferreira PCL, Prasadan A, et al. Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort. Alz Res Therapy. 2025;17:173.","journal-title":"Alz Res Therapy"},{"issue":"3","key":"ref24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s11682-020-00334-2","article-title":"Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study","volume":"15","author":"Sullivan KJ","year":"2021","unstructured":"Sullivan KJ, Liu A, Chang CH, et al. Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. Brain Imaging Behav. 2021;15(3):1355\u201363.","journal-title":"Brain Imaging Behav"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"669490","DOI":"10.3389\/fnagi.2021.669490","article-title":"Connectomics in Brain Aging and Dementia - The Background and Design of a Study of a Connectome Related to Human Disease","volume":"13","author":"Cohen AD","year":"2021","unstructured":"Cohen AD, Bru\u00f1a R, Chang YF, et al. Connectomics in Brain Aging and Dementia - The Background and Design of a Study of a Connectome Related to Human Disease. Front Aging Neurosci. 2021;13:669490.","journal-title":"Front Aging Neurosci"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41467-023-42834-x","article-title":"NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing","volume":"14","author":"Feng W","year":"2023","unstructured":"Feng W, Beer JC, Hao Q, et al. NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing. Nat Commun. 2023;14:7238.","journal-title":"Nat Commun"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","article-title":"Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease","volume":"19","author":"Zeng X","year":"2024","unstructured":"Zeng X, Lafferty TK, Sehrawat A, et al. Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease. Mol Neurodegeneration. 2024;19:68.","journal-title":"Mol Neurodegeneration"},{"issue":"21","key":"ref28","doi-asserted-by":"crossref","first-page":"e1920","DOI":"10.1212\/WNL.0000000000005549","article-title":"Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality","volume":"90","author":"Lopez OL","year":"2018","unstructured":"Lopez OL, Becker JT, Chang Y, et al. Amyloid deposition and brain structure as long-term predictors of MCI, dementia, and mortality. Neurology. 2018;90(21):e1920\u20138.","journal-title":"Neurology"},{"issue":"1","key":"ref29","first-page":"e12018","article-title":"Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non-demented older adults","volume":"12","author":"Snitz BE","year":"2020","unstructured":"Snitz BE, Tudorascu DL, Yu Z, et al. Associations between NIH Toolbox Cognition Battery and in vivo brain amyloid and tau pathology in non-demented older adults. Alzheimers Dement (Amst). 2020;12(1):e12018.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"11","key":"ref30","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.2967\/jnumed.123.265941","article-title":"Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies","volume":"64","author":"Gogola A","year":"2023","unstructured":"Gogola A, Lopresti BJ, Tudorascu D, et al. Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies. J Nucl Med. 2023;64(11):1798\u2013805.","journal-title":"J Nucl Med"},{"issue":"3","key":"ref31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","article-title":"Defining imaging biomarker cut points for brain aging and Alzheimer's disease","volume":"13","author":"Jack CR","year":"2017","unstructured":"Jack CR Jr, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease. Alzheimers Dement. 2017;13(3):205\u201316.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1214\/15-EJS1035","article-title":"Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates","volume":"9","author":"LeDell E","year":"2015","unstructured":"LeDell E, Petersen M, van der Laan M. Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates. Electron J Stat. 2015;9(1):1583\u2013607.","journal-title":"Electron J Stat"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze S","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease. Brain. 2023;146(4):1592\u2013601.","journal-title":"Brain"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/brain\/awae346","article-title":"A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests","volume":"148","author":"Warmenhoven N","year":"2025","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain. 2025;148(2):416\u201331.","journal-title":"Brain"},{"issue":"5","key":"ref35","doi-asserted-by":"crossref","first-page":"e70166","DOI":"10.1002\/alz.70166","article-title":"Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias","volume":"21","author":"Rea Reyes RE","year":"2025","unstructured":"Rea Reyes RE, Wilson RE, Langhough RE, et al. Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer's disease and related dementias. Alzheimers Dement. 2025;21(5):e70166.","journal-title":"Alzheimers Dement"},{"issue":"7","key":"ref36","doi-asserted-by":"crossref","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist S","year":"2025","unstructured":"Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"ref37","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1093\/brain\/awaa286","article-title":"Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease","volume":"143","author":"Mattsson-Carlgren N","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. Brain. 2020;143(11):3234\u201341.","journal-title":"Brain"},{"issue":"2","key":"ref38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41591-024-03400-0","article-title":"Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease","volume":"31","author":"Islam T","year":"2025","unstructured":"Islam T, Hill E, Abrahamson EE, et al. Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer's disease. Nat Med. 2025;31(2):574\u201388.","journal-title":"Nat Med"},{"issue":"8","key":"ref39","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie K","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat Med. 2023;29(8):1954\u201363.","journal-title":"Nat Med"},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease","volume":"31","author":"Horie K","year":"2025","unstructured":"Horie K, Salvad\u00f3 G, Koppisetti RK, et al. Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer's disease. Nat Med. 2025;31(6):2044\u201353.","journal-title":"Nat Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7754328\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7754328\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:07:03Z","timestamp":1770653223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-7754328\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":40,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-7754328\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1186\/s13195-026-01969-x","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2025,10,16]]},"subtype":"preprint"}}